Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Han, Yu
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients	Recruiting	3	477	RoW	transanal surgery, Miles surgery, Preoperative chemoradiotherapy	Zhang Rui	Almost-cCR, Surgery, Rectal Cancer	01/20	12/22
NCT05225844: An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal	Recruiting	2	150	RoW	Camrelizumab, Apatinib Mesylate	Harbin Medical University	Gastrointestinal Cancer, Immunotherapy, Targeted Therapy	02/22	10/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Han, Yu
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients	Recruiting	3	477	RoW	transanal surgery, Miles surgery, Preoperative chemoradiotherapy	Zhang Rui	Almost-cCR, Surgery, Rectal Cancer	01/20	12/22
NCT05225844: An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal	Recruiting	2	150	RoW	Camrelizumab, Apatinib Mesylate	Harbin Medical University	Gastrointestinal Cancer, Immunotherapy, Targeted Therapy	02/22	10/22